Health Care [ 8/12 ] | Pharmaceuticals [ 29/73 ]
NASDAQ | Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease.
The company also offers MZE001, a clinical program for the treatment of Pompe disease.
Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018.
The company was incorporated in 2017 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 25 | -0.75 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -32.79 M Decreased by -0.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -29.58 M Decreased by -11.30% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 2.50 M Increased by +N/A% | -24.75 M Decreased by -0.02% | Decreased by -990.08% Decreased by N/A% |
| Jun 30, 24 | 165.00 M - | 139.06 M - | Increased by +84.28% - |
| Mar 31, 24 | 0.00 - | -32.49 M - | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -26.58 M - | Decreased by N/A% - |
| Sep 30, 23 | 0.00 - | -24.75 M - | Decreased by N/A% - |